BIOGRAPHICAL SKETCH June 15, 2022 Jiri G. Safar Dr. Jiri G. Safar is Professor of Pathology, Neurology, and Neurosciences at Case Western Reserve University (CWRU). After completing his residency, chief residency, and PhD training in Biochemistry, he received Research Fellowship in the Laboratory of Central Nervous System Studies at the National Institutes of Health (NIH), directed by D.C. Gajdusek (Nobel Prize for Medicine 1976). In 1996, he took a position of a Senior Scientist at the Institute for Neurodegenerative Diseases, directed by Stanley B. Prusiner (Nobel Prize for Medicine 1997), and Associate Professor at the University of California at San Francisco (UCSF). In 2008, Dr. Safar was recruited to continue his research on neurodegenerative diseases caused by prions and protein misfolding at CWRU. His extensive research led to a discovery of previously unknown forms of prions and prion diseases, better understanding of the conformation of prion proteins, unraveling of the molecular mechanisms of prion strains, and development of new methods for detection and differentiation of prions. The fundamental concepts and tools he developed for prions provide a steppingstone for studies of growing number of age-related neurodegenerative diseases including Alzheimer’s disease and frontotemporal lobar degeneration (FTLD). Dr. Safar has authored 140 publications and holds 27 patents. For complete list of publications and further information: https://www.ncbi.nlm.nih.gov/myncbi/browse/collection/44043378/?sort=date&direction=descending

Prof. Türker ŞAHİNER, MD NEUROLOGY AND CLINICAL NEUROPHYSIOLOGY BEHAVIORAL SCIENCE Registered Province: Dinar /Afyon/Turkey Date of Birth : 1963 e-mail : turker.sahiner@memorial.com.tr Phone : +90 533 2414699

I have a psychology degree from the Jaume I University of Castellón de la Plana (Spain). I have a master's degree in the clinical specialty, it's called a master's degree in general health psychology from the University of Castilla-La Mancha. Nowadays, I'm a PhD student at the University of Castilla-La Mancha and I'm working in the department of Psychology as a researcher in the area of Basic Psychology

Dr. Salloway received his MD from Stanford Medical School and completed residencies in neurology and psychiatry at Yale University. He is the Martin M. Zucker Professor of Psychiatry and Human Behavior, and Professor of Neurology at the Warren Alpert Medical School of Brown University, the founding Director of the Memory and Aging Program at Butler Hospital, and the Associate Director of the Brown University Center for Alzheimer’s Disease Research. Dr. Salloway is an internationally recognized leader in clinical trials for the prevention and treatment of Alzheimer’s disease. His program has conducted more than 100 clinical trials for Alzheimer’s and related disorders. He has chaired the Steering Committees for major AD pivotal trials, such as bapineuzumab and aducanumab, and he has been a lead author for key publications in Alzheimer’s research in the New England Journal of Medicine, Nature and other top-tiered journals that have helped shaped the field of Alzheimer’s research. He also serves on the steering committees for major biomarker and clinical trials and consortia such as ADNI, DIAN, ACTC, and LEADS. He is the Past President of the American Neuropsychiatric Association, a Fellow of the American Academy of Neurology and a member of the American Neurological Association. He serves as a consultant for drug development to the NIH, the Alzheimer’s Association, the Alzheimer’s Disease Drug Discovery Foundation and many other groups working on Alzheimer’s therapeutics. He has published more than 400 scientific articles and abstracts and edited 3 books and he lectures widely about the early diagnosis and prevention of Alzheimer’s disease. In May 2019 he was elected to the Rhode Island Heritage Hall of Fame and was selected as the 2019 Rhode Island Man of the Year for his work on Alzheimer’s research.

Dr. Zimri is head of the Scientific Program, leading the research and development programs for ALS, Parkinson’s disease, and Alzheimer’s disease. Shiran is a pre-clinical drug development expert, with over 12 years of experience studying neurodegenerative diseases utilizing multidisciplinary methods. Shiran has vast expertise in leading projects and collaborations. Her work was published in leading journals and she presented her work at worldwide scientific conferences. She received multiple prizes and scholarships for her academic achievement. Dr. Zimri is a member of the BIO committee, a member of “Bashaar” – an academic community for society in Israel, and a member of “Midaat” -a non-profit organization promoting public health. Ph.D. in Neurobiology from Tel Aviv University.

Gemma Salvadó, PhD, is a post-doctoral researcher at Lund University (Sweden) in Dr. Oskar Hansson's group, granted with a Marie Skłodowska-Curie post-doctoral fellowship. She did her PhD at the Barcelonaβeta Brain Research Center (Spain) focused on the understanding of preclinical stages of Alzheimer's disease using neuroimaging and fluid biomarkers. During this period she also spent two periods of time at AmsterdamUMC (Netherlands) in different groups. Currently, she is working with plasma and CSF biomarkers to try to learn about the evolution of the disease. Among her other interests there are also reactive gliosis processes, modifiable and non-modifiable risk factors of Alzheimer's disease and vascular lesions.

Ph.D., Neuroscience, Louisiana State University Health Sciences Center-New Orleans, 2000 Postdoctoral. Aging and Parkinson's disease preclinical research, University of Kentucky Medical Center, 2001-2005 Current position: Professor, Pharmacology and Neuroscience, University of North Texas Health Science Center-Fort Worth Our work focuses on differential contributions of dopamine signaling in the substantia nigra and striatum on the motor impairments that characterize Parkinson's disease and aging-related parkinsonism. We have two major goals in this effort. 1) Elucidate the neurobiological mechanisms of lifestyle interventions, particularly exercise, that mitigate or locomotor impairment in aging-related parkinsonism and Parkinson’s disease, and 2) Optimize translation of neurobiological mechanisms from rodent Parkinson’s disease models into the human condition of Parkinson’s disease at all disease stages.

I'm a PhD Student at Sant Pau Memory Unit, and my research is focused on using super resolution microscopy techniques to unravel synaptic pathology in Alzheimer’s disease.